AUSTRALIAN AGED CARE GETS BOOSTER DOSE
BioSpectrum Asia
|BioSpectrum Asia June 2021
In 2017, there were 3.8 million Australians aged 65 and over (comprising 15 per cent of the total population) —increasing from 319,000 (5 per cent) in 1927 and 1.3 million (9 per cent) in 1977. The number and proportion of older Australians is expected to continue to grow. By 2057, it is projected that there will be 8.8 million older people in Australia (22 per cent of the population); by 2097, 12.8 million people (25 per cent) will be aged 65 and over according to Australian Bureau of Statistics (ABS) 2017. Looking at the growing trend, the government of Australia has a separate ministry for Senior Australians and Aged Care Services and undertaken many steps to support them with respect, care and dignity.
The Australian Government has taken an important step to deliver its reforms to aged care by introducing the first legislation in response to the Royal Commission into Aged Care Quality and Safety. The Aged Care and Other Legislation Amendment (Royal Commission Response No. 1) Bill 2021 has been introduced into Parliament on May 27, 2021, and makes necessary changes to current aged care legislation, ahead of the new Aged Care Act planned for 2023.
This bill is the first step in the Government’s five-year, five-pillar, aged care reform plan addressing home care, residential aged care services and sustainability, residential care quality and safety, workforce and governance. The health, safety and wellbeing of senior Australians is of the utmost importance to the government, and is driving its plan for generational change of the aged care sector.
Minister for Health and Aged Care, Greg Hunt, said that the amendments will deliver immediate priority changes around restrictive practices, home care assurance reviews, and repeal the Aged Care Financing Authority. “Regulating the use of restrictive practices, like chemical and physical restraint, is a critical focus for the Australian Government to improve quality and safety of aged care”, Minister Hunt said.
“Addressing concerns raised by the Royal Commission and the independent review into restraint, our amendments will mean from July 1, we will have clearly defined restrictive practices, which align with the definitions used in the disability sector. We are strengthening legislation to ensure that restrictive practices are only used as a last resort, the impact on the care recipient is considered, and consent arrangements are clear,” said Hunt.
Denne historien er fra BioSpectrum Asia June 2021-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
"The next 5-years will see mRNA science evolve beyond infectious disease"
A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.
4 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
No Funding No Vax for TB?
The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.
2 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Australia builds tailored heart pump to transform heart failure care
Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles
APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.
4 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia
Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026
In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.
1 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Fujifilm launches joint research with National Cancer Center in Japan
Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics
Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.
1 min
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Submitting clinical data to the FDA and PDMA: An efficient and compliant approach
In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.
2 mins
BioSpectrum Asia Dec 2025
BioSpectrum Asia
Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches
After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:
7 mins
BioSpectrum Asia Dec 2025
Translate
Change font size

